|
|
Higher serum bicarbonate associated with lower type 2 diabetes risk in Nurses Health Study. |
|
CMAJ: Interpretation: Higher plasma bicarbonate levels were associated with lower odds of incident type 2 diabetes mellitus among women in the Nurses' Health Study. Further studies are needed to confirm this finding in different populations and to elucidate the mechanism for this relation.
|
|
|
CMS announces initial group of practices participating in the ACO (Accountable Care Organization) model. |
|
CMS: Overview The Advance Payment Model is designed for physician-based and rural providers who have come together voluntarily to give coordinated high quality care to the Medicare patients they serve. Through the Advance Payment ACO Model, selected participants will receive upfront and monthly payments, which they can use to make important investments in their care coordination infrastructure. The following Advance Payment ACOs were announced for the performance period that began on April 1, 2012:
|
|
Patient weight gain after change of acid concentrate supplier with same nominal dialysate sodium level. |
|
IJAO: Conclusions: Changing dialysate acid concentrates, both labeled 1:44 dilution, led to the delivery of a higher dialysate sodium, resulting in weight gains, increased pre-dialysis blood pressure, but less symptomatic intradialytic hypotension. Following readjustment of volumetric dialysate mixing, excess weight gains and increased blood pressure resolved over 4 weeks, highlighting the importance of checking the delivered dialysate sodium following a change in dialysate acid concentrate.
|
|
New body shape index, based on height, BMI, and waist circumference, predicts mortality risk. |
|
PLOS online: Conclusions. Body shape, as measured by ABSI, appears to be a substantial risk factor for premature mortality in the general population derivable from basic clinical measurements. ABSI expresses the excess risk from high WC in a convenient form that is complementary to BMI and to other known risk factors.
|
|
JASN early release: Rituximab shows good results in membranous nephropathy. |
|
JASN: All 24 patients who had at least 4 years of follow-up achieved complete or partial remission. Rates of remission were similar between patients with or without previous immunosuppressive treatment. Four patients died and four progressed to ESRD. Measured GFR increased by a mean 13.2 (SD 19.6) ml/min per 1.73 m2 among those who achieved complete remission. Serum albumin significantly increased and albumin fractional clearance decreased among those achieving complete or partial remission. Proteinuria at baseline and the follow-up duration each independently predicted the decline of proteinuria. Furthermore, the magnitude of proteinuria reduction significantly correlated with slower GFR decline (P=0.0001). No treatment-related serious adverse events occurred. In summary, rituximab achieved disease remission and stabilized or improved renal function in a large cohort of high-risk patients with IMN.
|
|
|
|
|
<< Start < Prev 261 262 263 264 265 266 267 268 269 270 Next > End >>
|
|
Page 267 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
